Table 3. Antibiotic resistance patterns of the non-typhoidal Salmonella isolates from invasive infections identified among malaria vaccine trial (vaccine trial), central nervous system infection study (CNS study), and International Emerging Infections Program (surveillance program) participants during 2009–2014, Siaya county, Kenya.

CLSI Antimicrobial Class	Antimicrobiala	Vaccine trial		CNS study		Surveillance program
		Ceftriaxone-resistant isolates	Ceftriaxone-susceptible isolates	Ceftriaxone-resistant isolates	Ceftriaxone-susceptible isolates	Ceftriaxone-resistant isolates	Ceftriaxone-susceptible isolates
		n/N (%)	n/N (%)	n/N (%)	n/N (%)	n/N (%)	n/N (%)
Aminoglycosides	Gentamicin	16/16 (100)	0/74 (0)	16/16 (100)	0/2 (0)	9/11 (82)	5/154 (3)
	Kanamycin	14/15 (93)	1/74 (1)	16/16 (100)	0/0	9/11 (82)	11/154 (7)
	Streptomycin	6/6 (100)	59/64 (92)	15/16 (94)	2/2 (100)	11/11 (100)	138/155 (89)
β-lactam/β-lactamase inhibitor combinations	Amoxicillin-clavulanic acid	16/16 (100)	34/66 (52)	16/16 (100)	1/2 (50)	6/10 (60)	62/146 (42)
Cephems	Cefotaxime	1/1 (100)	0/1 (0)	0/0	0/0	0/0	0/0
Folate pathway inhibitors	Sulfisoxazole	13/13 (100)	34/40 (85)	16/16 (100)	2/2 (100)	11/11 (100)	140/154 (91)
	Trimethoprim-sulfamethoxazole	16/16 (100)	67/74 (91)	16/16 (100)	2/2 (100)	11/11 (100)	137/156 (88)
Penicillins	Ampicillin	16/16 (100)	63/70 (90)	15/16 (94)	2/2 (100)	11/11 (100)	135/155 (87)
Phenicols	Chloramphenicol	16/16 (100)	57/74 (77)	14/16 (88)	2/2 (100)	10/11 (91)	123/156 (79)
Quinolones	Ciprofloxacin	1/16 (6)	0/73 (0)	3/16 (19)	0/2 (0)	1/11 (9)	0/155 (0)
	Nalidixic acid	1/16 (6)	6/73 (8)	2/16 (13)	0/2 (0)	3/11 (27)	26/155 (17)
Tetracyclines	Tetracycline	13/13 (100)	12/24 (50)	15/16 (94)	0/2 (0)	10/11 (91)	60/156 (38)

Data are presented as No. (%) unless otherwise indicated.

CLSI, Clinical and Laboratory Standards Institute; CNS, central nervous system.

^aNot all isolates were tested for every antimicrobial listed.